Higashiosaka, Japan

Masaaki Tomoi

This inventor holds 1 USPTO granted patent. Top assignee: Aktiebolaget Hassle. Active years: 1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masaaki Tomoi. Retrieved from https://idiyas.com/inventor/masaaki-tomoi-plaubhaj

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masaaki Tomoi: Innovator in Antimicrobial Research

Introduction

Masaaki Tomoi is a notable inventor based in Higashiosaka, Japan. He has made significant contributions to the field of antimicrobial research, particularly through his innovative use of omeprazole.

Latest Patents

Masaaki Tomoi holds a patent for the "Use of omeprazole as an antimicrobial agent." This patent highlights his work in exploring the potential applications of existing medications in new therapeutic areas.

Career Highlights

Masaaki Tomoi is associated with Aktiebolaget Hassle, a company known for its pharmaceutical innovations. His work has contributed to advancements in antimicrobial treatments, showcasing his expertise in the field.

Collaborations

Masaaki has collaborated with notable coworkers, including Yoshifumi Ikeda and Yoshiko Yokota. These partnerships have likely enhanced the scope and impact of his research.

Conclusion

Masaaki Tomoi's contributions to antimicrobial research through his patent and collaborations reflect his dedication to innovation in the pharmaceutical industry. His work continues to influence the development of new therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…